Myelofibrosis treatment history and future prospects
Abstract Myelofibrosis (MF) is a haematopoietic stem cell tumour caused by the lack of BCR-ABL translocation due to point mutations in Janus kinases (JAKs). In previous years, dealing with MF included several protocols such as traditional drugs that control general symptoms, splenectomy, blood trans...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2022-11-01
|
| Series: | The Egyptian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43162-022-00169-x |
| _version_ | 1798018490720845824 |
|---|---|
| author | Amr Ghit |
| author_facet | Amr Ghit |
| author_sort | Amr Ghit |
| collection | DOAJ |
| description | Abstract Myelofibrosis (MF) is a haematopoietic stem cell tumour caused by the lack of BCR-ABL translocation due to point mutations in Janus kinases (JAKs). In previous years, dealing with MF included several protocols such as traditional drugs that control general symptoms, splenectomy, blood transfusion, and allogeneic haematopoietic stem-cell transplantation (HSCT). Allogeneic HSCT is remaining the only treatment that has the potential to alter MF’s progression. However, clinical trials of JAK inhibitors and non-JAK targeted therapies have been increasingly carried out in earlier years. The most prominent JAK inhibitors for the treatment of MF are ruxolitinib, fedratinib, momelotinib, pacritinib, gandotinib, ilginatinib, itacitinib, and lestaurtinib. On the other hand, the non-JAK targeted therapies that showed strong efficacy and safety are alisertib, imetelstat, pembrolizumab, nivolumab, and sotatercept. In this review, we summarized the recent clinical trials carried out on these drugs to understand their efficacy and safety. Also, we talked briefly about allogeneic HSCT as powerful therapy until the present for patients suffering from MF. |
| first_indexed | 2024-04-11T16:23:44Z |
| format | Article |
| id | doaj.art-be7dab7d5e09401c9e33eaf4951621a3 |
| institution | Directory Open Access Journal |
| issn | 1110-7782 2090-9098 |
| language | English |
| last_indexed | 2024-04-11T16:23:44Z |
| publishDate | 2022-11-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Internal Medicine |
| spelling | doaj.art-be7dab7d5e09401c9e33eaf4951621a32022-12-22T04:14:14ZengSpringerOpenThe Egyptian Journal of Internal Medicine1110-77822090-90982022-11-013411710.1186/s43162-022-00169-xMyelofibrosis treatment history and future prospectsAmr Ghit0Department of Medicine and Aging Sciences, “G. d’Annunzio” University of Chieti-PescaraAbstract Myelofibrosis (MF) is a haematopoietic stem cell tumour caused by the lack of BCR-ABL translocation due to point mutations in Janus kinases (JAKs). In previous years, dealing with MF included several protocols such as traditional drugs that control general symptoms, splenectomy, blood transfusion, and allogeneic haematopoietic stem-cell transplantation (HSCT). Allogeneic HSCT is remaining the only treatment that has the potential to alter MF’s progression. However, clinical trials of JAK inhibitors and non-JAK targeted therapies have been increasingly carried out in earlier years. The most prominent JAK inhibitors for the treatment of MF are ruxolitinib, fedratinib, momelotinib, pacritinib, gandotinib, ilginatinib, itacitinib, and lestaurtinib. On the other hand, the non-JAK targeted therapies that showed strong efficacy and safety are alisertib, imetelstat, pembrolizumab, nivolumab, and sotatercept. In this review, we summarized the recent clinical trials carried out on these drugs to understand their efficacy and safety. Also, we talked briefly about allogeneic HSCT as powerful therapy until the present for patients suffering from MF.https://doi.org/10.1186/s43162-022-00169-xMyelofibrosisTumourHaematopoietic stem-cell transplantationJanus kinasesRuxolitinib |
| spellingShingle | Amr Ghit Myelofibrosis treatment history and future prospects The Egyptian Journal of Internal Medicine Myelofibrosis Tumour Haematopoietic stem-cell transplantation Janus kinases Ruxolitinib |
| title | Myelofibrosis treatment history and future prospects |
| title_full | Myelofibrosis treatment history and future prospects |
| title_fullStr | Myelofibrosis treatment history and future prospects |
| title_full_unstemmed | Myelofibrosis treatment history and future prospects |
| title_short | Myelofibrosis treatment history and future prospects |
| title_sort | myelofibrosis treatment history and future prospects |
| topic | Myelofibrosis Tumour Haematopoietic stem-cell transplantation Janus kinases Ruxolitinib |
| url | https://doi.org/10.1186/s43162-022-00169-x |
| work_keys_str_mv | AT amrghit myelofibrosistreatmenthistoryandfutureprospects |